Aeolus Pharmaceuticals, Inc. Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals, Inc.

AOLS

Rank in Stocks #35173
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the... Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the development of innovative therapeutic compounds. Operating within the United States, the company's research pipeline addresses a diverse range of critical medical challenges, including biodefense, fibrotic conditions, oncology, infectious diseases, and central nervous system disorders. A core focus involves a distinct class of catalytic antioxidant compounds, which are being advanced as essential medical countermeasures against threats from nuclear, radiological, and chemical weapons, in addition to therapies for respiratory, neurological, and oncological ailments. Their flagship product candidate, AEOL 10150, has successfully navigated two Phase I clinical trials. This compound is being developed to combat the pulmonary complications associated with acute radiation syndrome, and also serves as a crucial protective agent against exposure to chemical vesicants and nerve agents. Further expanding its pipeline, Aeolus is also pursuing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, alongside AEOL 20415, designed to address various infectious diseases. Established in 1994, Aeolus Pharmaceuticals is headquartered in Mission Viejo, California.
Share Price
$0.000001
Last synced: 2026-11-10
Market Cap
$152.09
Change (1 day)
-99.00%
Change (1 year)
-99.00%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Aeolus Pharmaceuticals, Inc. (AOLS)

Category

Healthcare
EPS for Aeolus Pharmaceuticals, Inc. (AOLS)
EPS as of June 2017 TTM: $-0.03
According to Aeolus Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-0.03. At the end of 2016 the company had an EPS of $-0.04, a decrease compared to its 2015 EPS of $-0.02.
EPS history for Aeolus Pharmaceuticals, Inc. from 2000 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.03 -23.50%
2016 $-0.04 100.00%
2015 $-0.02 3,233.33%
2014 0.00 -98.01%
2013 $-0.03 -401.00%
2012 $0.01 100.00%
2011 $0.01 -100.94%
2010 $-0.53 703.03%
2009 $-0.07 -29.03%
2008 $-0.09 -7.00%
2007 $-0.10 -67.74%
2006 $-0.31 -36.73%
2005 $-0.49 -76.21%
2004 $-2.06 -5.50%
2003 $-2.18 -76.81%
2002 $-9.40 -66.15%
2001 $-27.77 162.97%
2000 $-10.56 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 -19,805.56%
DE
$6.01 -19,733.33%
DE
$1.53 -5,109.48%
JP
$3.66 -12,060.78%
CH
$0.45 -1,570.59%
IL

Questions about Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS)

What is Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS)?

Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-0.03, as of Jun 2017.

What was Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS) in 2016?

In 2016, Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS) was $-0.04, compared with $-0.02 in 2015.

How has Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2011?

From 2011 to 2016, Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2012 ($0.01) and lowest in 2016 ($-0.04).

How does Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?

Aeolus Pharmaceuticals, Inc.'s earnings per share (EPS) ($-0.03) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.